Pipeline

The Valeant Pipeline

Valeant's development pipeline strategy comprises new compounds as well as product life cycle management. The company's pipeline combines promising early and late-stage drug candidates that have unique formulations and mechanisms of action that address the need for new treatment regimens. Valeant also plans to strategically expand its pipeline by adding new compounds and product extensions through company and product acquisitions.

 

Valeant Pipeline Highlights

Product

Category

Description

Expected Timeline

Latanoprostene bunod

Eye Health

Glaucoma

2017 launch

Stellaris® Elite

Eye Health

Cataract and retinal surgery platform

2017 launch

Vitesse™

Eye Health

Hypersonic vitrectomy surgical device

2017 submission

Next generation Thermage®

Dermatology

Aesthetics device for addressing fine lines and wrinkles

2017 submission

Luminesse™

Eye Health

Ocular redness reliever

2017 submission

IDP-121

Dermatology

Acne

2017 submission

IDP-122

Dermatology

Psoriasis

2017 submission

IDP-118

Dermatology

Moderate-to-severe plaque psoriasis

2017 submission

Loteprednol Gel 0.38%

Eye Health

Ocular inflammation

2017 complete Phase lll enrollment

IDP-120

Dermatology

Acne

2017 initiate Phase III

IDP-123

Dermatology

Psoriasis

2017 initiate Phase lll